HOMEPAGE
Fully Diluted Subscribe

NYSE · Biotech stocks database

PFE — Pfizer Inc.

PFE (Pfizer Inc.) stock: $29.39, $167.52B market cap, $10.94B cash, $219.25B EV, $171.63B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of Pfizer Inc. 2025 Form 10-K 3 biopharmaceutical products worldwide.

Source: 10-K FY2025 via SEC EDGAR

Share price
$29.39
Market cap
$167,518.7M
Cash
$10,942.0M
Enterprise value
$219,247.7M

Balance sheet

Cash$10,942.0M
Debt$62,671.0M
Net cash-$51,729.0M
Enterprise value$219,247.7M
Basic shares5,699.9M shares
Fully diluted shares5,839.7M shares
Fully diluted market cap$171,628.0M
Cash per share$1.92
Quarterly burn+$835.0M generated

Cash figures as of 2026-09-27. Database snapshot: 2026-11-07.

Share structure

Common
5,699.7M
Pre-funded warrants
0.0M
Options
60.0M
RSUs
80.0M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.0M
FDSO
5,839.7M

Cap table as of 2026-06-28.

Price history

Loading PFE daily closes…

Loading price history…

Next catalyst

PF-07999415 · Now - Nov 13, 2026 Now · Phase 1 · Healthy

Recently reported

PF-07868489 Phase 1/2 Mixed · 2026-11-03
PF-07868489 · pulmonary hypertension
Primary: No trial endpoint result was reported; the item is Pfizer's termination, on business grounds, of the Phase 2 open-label extension study of PF-07868489 in pulmonary arterial hypertension — Pfizer terminated the study and attributed the action to business reasons, rather than safety or efficacy concerns; no efficacy data were disclosed
· Phase 1/2 trial of PF-07868489 began in 2023; the Phase 2 open-label extension began in 2025
· The extension study had been due to end in the second half of 2028
· The same quarterly clearout ended four other Phase 1 programs, including PF-07999415 in obesity and the KRAS inhibitors PF-07985045 and PF-07934040
Safety: Termination was attributed to business reasons, not safety concerns; no new safety data disclosed
Source release →
ELREXFIO (elranatamab) Phase 3 Positive · 2026-10-27
MagnetisMM-32 · relapsed/refractory multiple myeloma
Primary: Progression-free survival (PFS) as assessed by blinded independent central review (BICR) — Met the primary endpoint at the pre-specified interim analysis for efficacy: ELREXFIO demonstrated a statistically significant and clinically meaningful reduction in the risk of disease progression or death versus investigator's choice of EloPd, PVd, or Kd; median PFS not yet reached, with an estimated 68% PFS at 18 months
· 523 adults enrolled across 26 countries, each with at least one prior line of treatment with anti-CD38 therapy (daratumumab or isatuximab) and lenalidomide
· More than 75% of patients receiving ELREXFIO had not experienced disease progression or death from any cause at the time of the analysis
· Estimated 68% PFS at 18 months on ELREXFIO
· Overall survival (key secondary endpoint) immature; follow-up continues to the next pre-specified OS analysis
· Pfizer plans to submit these data to global health authorities
Safety: Safety profile consistent with the known profile of ELREXFIO, no new safety signals; Grade 3 or higher infections in 27.5% of patients receiving ELREXFIO vs 18.1% on investigator's choice, and Grade 5 infections in 0.8% vs 1.6%
Source release →
PF-06835375 Phase 2 Mixed · 2026-10-20
primary immune thrombocytopenia
Primary: Not disclosed in the source report; the trial was terminated before any readout — terminated due to a business decision
· Final enrollment 61 participants vs 91 planned
· Phase 2, open-label, began 2022
· Pfizer stated the decision was not based on any safety concerns
· No efficacy data were disclosed
· Pfizer would not confirm whether all work on PF-06835375 has been halted
Safety: Termination explicitly not based on safety concerns; no safety data disclosed
Source release →
Ritlecitinib Phase 3 Mixed · 2026-10-02
F-VASI75
Source release →
PF-07275315 Phase 2 Mixed · 2026-10-01
PF-07275315
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego